Comment on: "Premedication prior to PEG-asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia"

Pediatr Blood Cancer. 2022 Apr;69(4):e29474. doi: 10.1002/pbc.29474. Epub 2021 Dec 10.

Authors

Wing H Tong^{1

2}, Carin A Uyl-De Groot^{3

4}

Affiliations

¹ Department of Public Health and Primary Care (PHEG), Leiden University Medical Center, Leiden, The Netherlands.
² Argos Zorggroep "DrieMaasStede", Center for Specialized Geriatric Care, Schiedam, The Netherlands.
³ Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
⁴ Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.

PMID: 34889044
DOI: 10.1002/pbc.29474

No abstract available

Publication types

Letter
Comment

MeSH terms

Asparaginase / therapeutic use
Child
Cost-Benefit Analysis
Dickeya chrysanthemi*
Humans
Polyethylene Glycols / therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Premedication
Technology

Substances

Polyethylene Glycols
pegaspargase
Asparaginase